Affinage · Toxoplasma gondii

AP2IV4

AP2 domain transcription factor AP2IV-4 · UniProt S8FCP8

Annotated
2026-09-10
11 papers in source corpus 2 papers cited in narrative 3 extracted findings

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

AP2IV-4 is a nuclear ApiAP2 transcriptional repressor that enforces the tachyzoite gene expression program of Toxoplasma gondii by suppressing bradyzoite-specific antigens during acute infection (PMID:29718996). It is one of a series of AP2 factors expressed in a cell-cycle-resolved manner, with protein levels peaking sharply from late S phase through mitosis/cytokinesis of the tachyzoite cycle (PMID:29718996, PMID:20865045). Deletion of the locus derepresses bradyzoite-stage proteins (BPK1, MCP4, CST1, SRS9) in replicating tachyzoites, identifying these antigens as targets of AP2IV-4-mediated repression (PMID:29718996). This repression is required for chronic infection: in an immune-competent murine model, premature misexpression of bradyzoite antigens in AP2IV-4 knockout parasites elicits an inflammatory monocyte response that clears the parasite and blocks brain tissue cyst formation (PMID:29718996). The direct promoter targets bound by the AP2 domain and the mechanism of its stage-specific action have not been characterized beyond these findings in the available corpus.

Mechanistic history

Synthesis pass · year-by-year structured walk · 3 steps
  1. 2010 Medium

    Before any function was assigned, it was unknown whether AP2IV-4 was regulated in a cell-cycle-dependent manner; profiling placed it within a temporally ordered series of AP2 factors, framing it as a candidate stage/cycle-specific transcription factor.

    Evidence Genome-wide cell cycle transcriptome and protein expression profiling across tachyzoite stages

    PMID:20865045

    Open questions at the time
    • No direct functional perturbation of AP2IV-4 in this study
    • Promoter targets and DNA-binding specificity not defined
    • Repressor versus activator role not established
  2. 2018 High

    It was unknown what genes AP2IV-4 controlled; gene deletion showed it represses bradyzoite-specific antigens in replicating tachyzoites, establishing it as a repressor that maintains the acute-stage program.

    Evidence Gene deletion with immunofluorescence for nuclear localization, cell-cycle expression timing, and analysis of bradyzoite antigen derepression (BPK1, MCP4, CST1, SRS9)

    PMID:29718996

    Open questions at the time
    • Direct promoter binding of the AP2 domain to these target genes not demonstrated
    • Co-repressor partners or chromatin machinery not identified
    • Mechanism linking cell-cycle timing to target repression unresolved
  3. 2018 High

    It was unknown whether bradyzoite antigen repression by AP2IV-4 mattered for infection outcome; in vivo knockout showed derepression triggers an inflammatory monocyte response that clears the parasite and prevents cyst formation, establishing AP2IV-4-mediated suppression as required for chronic infection.

    Evidence Mouse infection with AP2IV-4 knockout parasites, inflammatory monocyte readouts, and brain cyst burden quantification

    PMID:29718996

    Open questions at the time
    • Which specific derepressed antigen(s) drive the immune clearance not resolved
    • Behavior across parasite strains not addressed
    • Role in natural (non-murine) hosts unknown

Open questions

Synthesis pass · forward-looking unresolved questions
  • Whether AP2IV-4 binds its bradyzoite target promoters directly and what co-factors or chromatin machinery mediate repression remains open.
  • No direct DNA-binding/ChIP data linking AP2IV-4 to target promoters in the corpus
  • No identified interacting repressor complex
  • Mechanistic coupling of cell-cycle expression timing to repression not established

Mechanism profile

Synthesis pass · controlled-vocabulary classification
No controlled-vocabulary terms were assigned to this entry.

Evidence

Reading pass · 3 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2018 AP2IV-4 is a nuclear transcriptional repressor dynamically expressed in late S phase through mitosis/cytokinesis of the tachyzoite cell cycle. Deletion of the AP2IV-4 locus resulted in the aberrant expression of bradyzoite-specific proteins (BPK1, MCP4, CST1, SRS9) in replicating tachyzoites, establishing AP2IV-4 as a repressor of bradyzoite antigen expression during acute infection. Gene deletion (KO), immunofluorescence for nuclear localization, Western blot for protein expression timing, transcriptomic/protein analysis of bradyzoite-specific antigens in tachyzoites lacking AP2IV-4 PLoS pathogens High 29718996
2018 In the murine animal model, misexpression of bradyzoite antigens in tachyzoites lacking AP2IV-4 elicited a potent inflammatory monocyte immune response that eliminated the parasite and prevented tissue cyst formation in mouse brain tissue, demonstrating that AP2IV-4-mediated suppression of bradyzoite antigens is required for Toxoplasma to establish chronic infection in an immune-competent host. Mouse infection model with AP2IV-4 knockout parasites, immunological readouts (inflammatory monocyte response), brain cyst burden quantification PLoS pathogens High 29718996
2010 AP2IV-4 protein expression peaks sharply during the tachyzoite cell cycle in a timeframe consistent with its mRNA pattern, suggesting that mechanisms responsible for the timing of protein delivery may be mediated by AP2 domain promoter recognition specificities. AP2IV-4 was identified as one of ~24 AP2 transcription factors forming a series through the tachyzoite cycle. Genome-wide cell cycle transcriptome analysis, protein expression profiling across tachyzoite cell cycle stages PloS one Medium 20865045

Source papers

Stage 0 corpus · 11 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2010 Coordinated progression through two subtranscriptomes underlies the tachyzoite cycle of Toxoplasma gondii. PloS one 234 20865045
2018 Transcriptional repression by ApiAP2 factors is central to chronic toxoplasmosis. PLoS pathogens 77 29718996
2018 The Epigenome, Cell Cycle, and Development in Toxoplasma. Annual review of microbiology 51 29932347
2010 The construction and use of log-odds substitution scores for multiple sequence alignment. PLoS computational biology 48 20657661
2008 Repeated secondary loss of adaptin complex genes in the Apicomplexa. Parasitology international 36 19146987
2012 Cactin is essential for G1 progression in Toxoplasma gondii. Molecular microbiology 23 22486860
2014 Distinct strains of Toxoplasma gondii feature divergent transcriptomes regardless of developmental stage. PloS one 22 25393307
2008 New eukaryotic systematics: a phylogenetic perspective of developmental gene expression in the Apicomplexa. International journal for parasitology 12 18983845
2024 Apicomplexan mitoribosome from highly fragmented rRNAs to a functional machine. Nature communications 9 39690155
2022 Genomic insights into host and parasite interactions during intracellular infection by Toxoplasma gondii. PloS one 2 36178892
2026 Host-cell dependent epigenetic profiles associated with survival outcomes in T. gondii infection. Epigenetics & chromatin 0 42087241